

RareTi Co-Founder Wendy White Named to ICORD Board

Chicago - April 29, 2021

RareTi Co-Founder Wendy White has joined the board of ICORD, the International Collaboration on Rare Diseases and Orphan Drugs. ICORD brings researchers, academics, drug developers, HCPs, regulators and policymakers together to improve the welfare of patients with rare diseases.

White has been an innovator in charting pathways for rare disease patients to gain access to emerging therapies, first by connecting pharma and rare disease communities at Siren Interactive, a digital agency she formed, and now at RareTi, where she has joined with co-founder Natalie Douglas to provide technology-enabled Managed Access Programs. RareTi is focused on enabling orphan drug developers to provide access to a broader set of patients through managed access programs world-wide.



“ICORD provides a forum to share the best ideas arising from all channels in rare disease,” said White. “If those ideas can improve the outcomes or provide access to even a few patients, we will have made a world of difference. I look forward to advancing ICORD’s mission of inspiring global collaboration among all rare disease stakeholders.”

About RareTi

RareTi offers a new Managed Access model to the pharmaceutical industry delivering solutions to meet the unmet needs of people and communities across the globe impacted by rare disease. Our Managed Access and patient support programs provide care beyond therapy, combining customizable solutions with white glove service. We combine a breadth of global experience, cutting edge technologies and analytics that deliver better outcomes. To find out more, visit www.rareiti.com or email us at info@rareiti.com.